Sinha B, Semmler J, Eisenhut T, Eigler A, Endres S
Medizinische Klinik, Ludwig-Maximilians-Universität, München, Germany.
Eur J Immunol. 1995 Jan;25(1):147-53. doi: 10.1002/eji.1830250125.
We investigated cooperative effects of phosphodiesterase (PDE) inhibitors and prostanoids on cyclic adenosine monophosphate (cAMP) accumulation and tumor necrosis factor (TNF)-alpha synthesis in human peripheral blood mononuclear cells (PBMC). PDE inhibitors alone induced only a small increase in cAMP levels in lipopolysaccharide (LPS)-stimulated PBMC. Cicaprost (a stable analogue of prostacyclin) and pentoxifylline added simultaneously to LPS-stimulated PBMC (2.0 x 10(6)/ml) induced a rapid increase of cAMP to a level of 100 nM that peaked within 10 min and remained at a plateau for up to 4 h. Thus combined prostanoids and PDE inhibitors enhanced cAMP accumulation. TNF-alpha suppression in the presence of pentoxifylline and prostanoids exceeded that of either drug alone. The potency of different PDE inhibitors (theophylline, pentoxifylline, penthydroxifylline, albifylline, torbafylline, A 80 2715, amrinone and rolipram) to increase cAMP levels in combination with cicaprost was evaluated after 1 h of incubation. The dose-dependent increase of cAMP for all PDE inhibitors tested in this combined stimulation provided a useful tool for evaluating the potency of PDE inhibitors on cAMP accumulation. The effective concentration of PDE inhibitors, which raised cAMP levels to 300% of control, (EC300), correlated with the IC50 for TNF-alpha suppression (r = 0.930, p = 0.007, with theophylline excluded from the analysis). Interestingly, by contrast, the specific type IV PDE inhibitor rolipram caused only a moderate rise of accumulated cAMP in the same cells. Our data support cAMP as an essential mediator for TNF-alpha suppression by PDE inhibitors. Furthermore, an enhanced inhibiting effect on TNF-alpha production may prove therapeutically advantageous. It may occur in inflammatory and infectious diseases in vivo, since high levels of endogenous prostaglandins are liberated in these conditions.
我们研究了磷酸二酯酶(PDE)抑制剂和前列腺素类药物对人外周血单核细胞(PBMC)中环磷酸腺苷(cAMP)积累及肿瘤坏死因子(TNF)-α合成的协同作用。单独使用PDE抑制剂仅能使脂多糖(LPS)刺激的PBMC中的cAMP水平有小幅升高。将西卡前列素(前列环素的一种稳定类似物)和己酮可可碱同时添加到LPS刺激的PBMC(2.0×10⁶/ml)中,可使cAMP迅速升高至100 nM的水平,在10分钟内达到峰值,并在长达4小时内保持在平台期。因此,前列腺素类药物和PDE抑制剂联合使用可增强cAMP的积累。在己酮可可碱和前列腺素类药物存在的情况下,TNF-α的抑制作用超过了单独使用任何一种药物的情况。孵育1小时后,评估了不同PDE抑制剂(茶碱、己酮可可碱、五羟可可碱、阿比可可碱、托巴茶碱、A 80 2715、氨力农和咯利普兰)与西卡前列素联合使用时提高cAMP水平的效力。在这种联合刺激中,所有测试的PDE抑制剂使cAMP呈剂量依赖性增加,这为评估PDE抑制剂对cAMP积累的效力提供了一个有用的工具。将cAMP水平提高至对照水平300%的PDE抑制剂有效浓度(EC300)与TNF-α抑制的IC50相关(r = 0.930,p = 0.007,分析中排除了茶碱)。有趣的是,相比之下,特异性IV型PDE抑制剂咯利普兰在相同细胞中仅使积累的cAMP有适度升高。我们的数据支持cAMP作为PDE抑制剂抑制TNF-α的重要介质。此外,对TNF-α产生的增强抑制作用可能在治疗上具有优势。它可能发生在体内的炎症和感染性疾病中,因为在这些情况下会释放高水平的内源性前列腺素。